Share on LinkedInShare on LinkedIn

ARTICLE · 06 FEBRUARY 2023

EMA To Reinstate Its Proactive Clinical Data Publication Policy

EMA has decided to restart implementation of its policy to proactively publish clinical data.

United StatesConsumer Protection

The EMA has announced the decision of its management board to resume its proactive clinical data publication policy after a four year-long pause. The application of the proactive publication policy will follow a staggered approach where priority will be given to data relating to new marketing authorization applications that involve new active substances.

A decision to suspend publication of clinical data was made in December 2018 to support EMA's operational continuity during re-location of its headquarters from London to Amsterdam following the UK's withdrawal from the European Union. Clinical data relating to treatments and vaccines for COVID-19, however, continued to be published during this time on an exceptional basis to meet public demand for publication of information, facilitate global research and enhance trust in related regulatory decisions across the EU.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from